• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Where Does AnaptysBio (ANAB) Valuation Sit On Its Latest Earnings Reset?

    Simply Wall St·11/13/2026 08:24:20
    Listen to the news

    AnaptysBio (ANAB) just reported first quarter results for the period ended September 30, 2026, reporting net income of US$3.88 million and basic earnings per share from continuing operations of US$0.13.

    Against that earnings backdrop, AnaptysBio’s share price closed at US$47.77, with the stock slipping 2.05% over the last day but gaining 2.84% over the past week as investors digest the lower quarterly profit versus a year ago.

    In the short term, the 30 day share price return of 2.36% contrasts with a 90 day share price decline of 18.30%. Over a 1 year period, the total shareholder return of 111.90% and the roughly 4x 3 year total shareholder return indicate that longer term holders have fared differently from those focused on more recent momentum.

    Capitalize on AnaptysBio’s earnings reset by scanning a curated group of biotech and high-potential healthcare stocks through our 20 high quality undiscovered gems.

    AnaptysBio has already delivered a very large 1 year return, yet the recent pullback and earnings reset leave a clear tension. Has most of the upside already played out, or does the valuation still offer meaningful headroom?

    Most Popular Narrative: 47% Undervalued

    AnaptysBio closed at $47.77 while the leading narrative-based fair value sits at $90, which frames the current reset as a potential valuation gap rather than just a cooling off after large gains. According to TripleS, an investor in the Simply Wall St Community who wrote the narrative, that gap hinges on how royalty cash flows and legal outcomes play out over the next few years.

    A few months ago, ANAB spun its entire drug development pipeline into First Tracks Bio (TRAX), one share for one share. This results in a huge drop in future capex expenses as a result.

    What stayed behind was a two drug pure play royalty business with ~$140 million net cash, fewer than 10 Full Time Employees operating as contractors, under $10M in annualized OpEx against a nine-figure royalty stream, and a buyback program.

    See why 3 investors see AnaptysBio as 47% undervalued.

    The narrative applies a discount rate of 7.44% to those royalty streams and arrives at a fair value of $90 per share. This sits well above both the last close and the $87.25 analyst price target. That view sits alongside the platform’s own DCF work, which estimates AnaptysBio is trading 71.3% below a future cash flow value of $166.17. This implies that a lot of the current price reflects caution around execution, litigation and funding structure rather than the bare math of projected inflows.

    Against that backdrop, the stock also screens as good value relative to peers. The system flags AnaptysBio as attractive on several checks and assigns a value score of 5 out of 6. At the same time, forecasts point to roughly 30% annual revenue growth but a modest average earnings decline of 0.2% a year over the next three years. This suggests that modelled profitability is sensitive to items like non cash earnings, interest coverage and the timing of royalty monetisation deals.

    Pulling it together, the most popular narrative leans heavily on high margin royalty economics, a finite Sagard obligation and potential legal outcomes with GSK. The structured valuation tools, in contrast, focus on discounted cash flows and relative pricing signals. Both approaches highlight a sizeable gap between current market pricing and internally assessed value, although each rests on different assumptions about how quickly cash flows accrue to common shareholders and how sustainable recent profitability really is.

    Result: Fair Value of $90 (UNDERVALUED)

    Still, the AnaptysBio story leans heavily on ongoing Jemperli royalties and favorable litigation outcomes. Any setback on either front could undercut that thesis.

    Find out about the key risks to this AnaptysBio narrative.

    Next Steps

    If the mixed mood around AnaptysBio has you undecided, move fast and ground your view in facts by weighing both the upside drivers and the pressure points highlighted by the data. To see that full picture in one place, including 4 key rewards and 3 important warning signs.

    Looking for more investment ideas beyond AnaptysBio?

    Do not stop with AnaptysBio. Broaden your watchlist now, because the next opportunity that fits your style might already be on someone else's radar.